ScholarIQanswers from OpenAlex & ORCID
Eiji Oki
ResearcherPublications, citations & collaboration network
Eiji Oki is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Eiji Oki have?
ScholarIQindexed works
Eiji Oki has 1,194 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Eiji Oki have?
ScholarIQcitation count
Eiji Oki has 19,419 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Eiji Oki?
ScholarIQh-index
Eiji Oki has an h-index of 71 in OpenAlex.
What is the i10-index of Eiji Oki?
ScholarIQi10-index
Eiji Oki has an i10-index of 382 in OpenAlex.
What is the ORCID of Eiji Oki?
ScholarIQorcid
The ORCID for Eiji Oki is on the source record.
What is the OpenAlex record for Eiji Oki?
ScholarIQopenalex
The OpenAlex for Eiji Oki is on the source record.
What are the most-cited papers on Eiji Oki?
ScholarIQmost cited works
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura, Hiroki Yukami, Saori Mishima, Hideaki Bando, Hiromichi Shirasu, Kentaro Yamazaki, Jun Watanabe, Masahito Kotaka, Keiji Hirata, Naoya Akazawa, Kozo Kataoka, Shruti Sharma, Vasily N. Aushev, Alexey Aleshin, Toshihiro Misumi, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Takayuki Yoshino
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Hideaki Bando, Ken Kato, Chigusa Morizane, Taito Esaki, Yoshito Komatsu, Yasuyuki Kawamoto, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hisato Kawakami, Eiji Oki, Takako Eguchi Nakajima, Naohiro Nishida, Kensei Yamaguchi, Hisateru Yasui, Masahiro Goto, Nobuhisa Matsuhashi, Koushiro Ohtsubo, Kentaro Yamazaki, Akihito Tsuji, Wataru Okamoto, Katsuya Tsuchihara, Takeharu Yamanaka, Miki Izumi, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I. Odegaard, Takayuki Yoshino
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer
Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Keiji Hirata, Kozo Kataoka, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Yoshinori Kagawa, Kun‐Huei Yeh, Saori Mishima, Hiroki Yukami, Koji Ando, Masaaki Miyo, Toshihiro Misumi, Kentaro Yamazaki, Hiromichi Ebi, Kenji Okita, Atsushi Hamabe, Hiroki Sokuoka, Satoshi Kobayashi, George Laliotis, Vasily N. Aushev, Shruti Sharma, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Matthew Rabinowitz, Hideaki Bando, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Daisuke Kotani, Masaki Mori, Takayuki Yoshino, Eiji Oki